Avalo Therapeutics (AVTX) Non-Current Deferred Tax Liability (2017 - 2025)
Avalo Therapeutics filings provide 9 years of Non-Current Deferred Tax Liability readings, the most recent being $434000.0 for Q4 2025.
- On a quarterly basis, Non-Current Deferred Tax Liability fell 69.65% to $434000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $434000.0, a 69.65% decrease, with the full-year FY2025 number at $434000.0, down 69.65% from a year prior.
- Non-Current Deferred Tax Liability hit $434000.0 in Q4 2025 for Avalo Therapeutics, up from $304000.0 in the prior quarter.
- In the past five years, Non-Current Deferred Tax Liability ranged from a high of $1.4 million in Q4 2024 to a low of $111000.0 in Q1 2021.
- Median Non-Current Deferred Tax Liability over the past 5 years was $154500.0 (2023), compared with a mean of $242300.0.
- Biggest five-year swings in Non-Current Deferred Tax Liability: soared 822.58% in 2024 and later tumbled 69.65% in 2025.
- Avalo Therapeutics' Non-Current Deferred Tax Liability stood at $113000.0 in 2021, then grew by 24.78% to $141000.0 in 2022, then increased by 9.93% to $155000.0 in 2023, then soared by 822.58% to $1.4 million in 2024, then tumbled by 69.65% to $434000.0 in 2025.
- The last three reported values for Non-Current Deferred Tax Liability were $434000.0 (Q4 2025), $304000.0 (Q3 2025), and $293000.0 (Q2 2025) per Business Quant data.